ArticleOncotarget2023

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).

Leo I Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.